Enlivex: Jumps on positive data from experimental COVID-19 therapy study

Enlivex

03/02/2021 13:52

** U.S.-listed shares of Israel-based drug developer
 ENLV.O  surge 30% to $17 premarket
    ** ENLV reports positive top-line results from its mid-stage
study testing its experimental therapy Allocetra in severe and
critical COVID-19 patients (https://refini.tv/2Leh3A2)
    ** Co says 14 of 16 patients treated with Allocetra until a
certain date recovered completely and were discharged from
hospital, an avg. of 5.3 days after treatment
    ** Based on positive results, ENLV has completed the trial
early and plans to submit data summary to regulators later this
month
    ** Co says mortality rate at 28 days post-Allocetra
treatment for participants was 0%
    ** Allocetra is also being tested to treat patients with
organ failure associated with sepsis
    ** Up to last close, stock up 54.8% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))